tbuckley/cabot-search huggingface dataset:
Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome
Authors: Oscar Westin, Emil L Fosbøl, Mathew S Maurer, Birgitte P Leicht, Philip Hasbak, Anne Kærsgaard Mylin, Sara Rørvig, Thomas Hartvig Lindkær, Helle Hjorth Johannesen, Finn Gustafsson
Journal: Journal of the American College of Cardiology (2022)
Pathophysiologic Processes and Novel Biomarkers Associated With Congestion in Heart Failure
Authors: Paloma Pandhi, Jozine M. ter Maaten, Stefan D. Anker, Leong L. Ng, Marco Metra, Nilesh J. Samani, Chim C. Lang, Kenneth Dickstein, Rudolf A. de Boer, Dirk J. van Veldhuisen, Adriaan A. Voors, Iziah E. Sama
Journal: JACC Heart Failure (2022)
Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy With Impaired Left Ventricular Function
Authors: Trejeeve Martyn, Joshua Saef, Anusha Ray Dey, Rola Khedraki, Vardhmaan Jain, Patrick Collier, Wael A. Jaber, Jerry D. Estep, Mazen Hanna, W.H. Wilson Tang
Journal: JACC Heart Failure (2022)
Ischemic Heart Disease in Young Women
Authors: Margo B. Minissian, Puja K. Mehta, Sharonne N. Hayes, Ki Park, Janet Wei, C. Noel Bairey Merz, Leslie Cho, Annabelle Santos Volgman, Islam Y. Elgendy, Mamas Mamas, Melinda B. Davis, Harmony R. Reynolds, Kelly Epps, Kathryn Lindley, Malissa Wood, Odayme Quesada, Gregory Piazza, Carl J. Pepine
Journal: Journal of the American College of Cardiology (2022)
Cathepsin S Levels and Survival Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes
Authors: Kimon Stamatelopoulos, Matthias Mueller-Hennessen, Georgios Georgiopoulos, Pedro Lopez-Ayala, Marco Sachse, Nikolaos I. Vlachogiannis, Kateryna Sopova, Dimitrios Delialis, Francesca Bonini, Raphael Patras, Giorgia Ciliberti, Mehrshad Vafaie, Moritz Biener, Jasper Boeddinghaus, Thomas Nestelberger, Luca Koechlin, Simon Tual-Chalot, Ioannis Kanakakis, Aikaterini Gatsiou, Hugo Katus, Ioakim Spyridopoulos, Christian Mueller, Evangelos Giannitsis, Konstantinos Stellos
Journal: Journal of the American College of Cardiology (2022)

Patients with non–ST-segment elevation acute coronary syndromes (NSTE-ACS) are at high residual risk for long-term cardiovascular (CV) mortality. Cathepsin S (CTSS) is a lysosomal cysteine protease with elastolytic and collagenolytic activity that has been involved in atherosclerotic plaque rupture. The purpose of this study was to determine the following: 1) the prognostic value of circulating CTSS measured at patient admission for long-term mortality in NSTE-ACS; and 2) its additive value over the GRACE (Global Registry of Acute Coronary Events) risk score. This was a single-center cohort study, consecutively recruiting patients with adjudicated NSTE-ACS (n = 1,112) from the emergency department of an academic hospital. CTSS was measured in serum using enzyme-linked immunosorbent assay. All-cause mortality at 8 years was the primary endpoint. CV death was the secondary endpoint. In total, 367 (33.0%) deaths were recorded. CTSS was associated with increased risk of all-cause mortality (HR for highest vs lowest quarter of CTSS: 1.89; 95% CI: 1.34-2.66; P < 0.001) and CV death (HR: 2.58; 95% CI: 1.15-5.77; P = 0.021) after adjusting for traditional CV risk factors, high-sensitivity C-reactive protein, left ventricular ejection fraction, high-sensitivity troponin-T, revascularization and index diagnosis (unstable angina/ non–ST-segment elevation myocardial infarction). When CTSS was added to the GRACE score, it conferred significant discrimination and reclassification value for all-cause mortality (Delta Harrell's C: 0.03; 95% CI: 0.012-0.047; P = 0.001; and net reclassification improvement = 0.202; P = 0.003) and CV death (AUC: 0.056; 95% CI: 0.017-0.095; P = 0.005; and net reclassification improvement = 0.390; P = 0.001) even after additionally considering high-sensitivity troponin-T and left ventricular ejection fraction. Circulating CTSS is a predictor of long-term mortality and improves risk stratification of patients with NSTE-ACS over the GRACE score.
Preoperative data-based deep learning model for predicting postoperative survival in pancreatic cancer patients
Authors: Woohyung Lee, Hyo Jung Park, Hack-Jin Lee, Eunsung Jun, Ki Byung Song, Dae Wook Hwang, Jae Hoon Lee, Kyongmook Lim, Namkug Kim, Seung Soo Lee, Jae Ho Byun, Hyoung Jung Kim, Song Cheol Kim
Journal: International Journal of Surgery (2022)
Decision-making process during limitation life-sustaining support meetings in French intensive care units
Authors: Terry Tarcy, Hatem Kallel, Mathilde Giffard, Guillaume Besch, Régis Aubry, Régis Aubry, Guillaume Besch, Laurent Carteron, Mathilde Giffard, Hatem Kallel, Séverine Matheus, Gael Piton, Jean Marc Pujo, Jean-Pierre Quenot, Terry Tarcy, Hadrien Winiszewski
Journal: Intensive Care Medicine (2022)
Low-dose decitabine modulates myeloid-derived suppressor cell fitness via LKB1 in immune thrombocytopenia
Authors: Xiaofei Ni, Lingjun Wang, Haoyi Wang, Tianshu Yu, Jie Xie, Guosheng Li, Yanfeng Liu, Hai Zhou, Miao Xu, Ming Hou, Jun Peng, Yu Hou
Journal: Blood (2022)
Routine Pressure Wire Assessment Versus Conventional Angiography in the Management of Patients With Coronary Artery Disease: The RIPCORD 2 Trial
Authors: Rodney H. Stables, Liam J. Mullen, Mostafa Elguindy, Zoe Nicholas, Yousra H. Aboul-Enien, Ian Kemp, Peter O’Kane, Alex Hobson, Thomas W. Johnson, Sohail Q. Khan, Stephen B. Wheatcroft, Scot Garg, Azfar G. Zaman, Mamas A. Mamas, James Nolan, Sachin Jadhav, Colin Berry, Stuart Watkins, David Hildick-Smith, Julian Gunn, Dwayne Conway, Angels Hoye, Iftikhar A. Fazal, Colm G. Hanratty, Bernard De Bruyne, Nick Curzen
Journal: Circulation (2022)

Measurement of fractional flow reserve (FFR) has an established role in guiding percutaneous coronary intervention. We tested the hypothesis that, at the stage of diagnostic invasive coronary angiography, systematic FFR-guided assessment of coronary artery disease would be superior, in terms of resource use and quality of life, to assessment by angiography alone.We performed an open-label, randomized, controlled trial in 17 UK centers, recruiting 1100 patients undergoing invasive coronary angiography for the investigation of stable angina or non-ST-segment-elevation myocardial infarction. Patients were randomized to either angiography alone (angiography) or angiography with systematic pressure wire assessment of all epicardial vessels >2.25 mm in diameter (angiography+FFR). The coprimary outcomes assessed at 1 year were National Health Service hospital costs and quality of life. Prespecified secondary outcomes included clinical events.In the angiography+FFR arm, the median number of vessels examined was 4 (interquartile range, 3-5). The median hospital costs were similar: angiography, £4136 (interquartile range, £2613-£7015); and angiography+FFR, £4510 (£2721-£7415; P=0.137). There was no difference in median quality of life using the visual analog scale of the EuroQol EQ-5D-5L: angiography, 75 (interquartile range, 60-87); and angiography+FFR, 75 (interquartile range, 60-90; P=0.88). The number of clinical events was as follows: deaths, 5 versus 8; strokes, 3 versus 4; myocardial infarctions, 23 versus 22; and unplanned revascularizations, 26 versus 33, with a composite hierarchical event rate of 8.7% (48 of 552) for angiography versus 9.5% (52 of 548) for angiography+FFR (P=0.64).A strategy of systematic FFR assessment compared with angiography alone did not result in a significant reduction in cost or improvement in quality of life.URL: https://www.gov; Unique identifier: NCT01070771.
A Blood-Based Metabolite Panel for Distinguishing Ovarian Cancer from Benign Pelvic Masses
Authors: Ehsan Irajizad, Chae Y. Han, Joseph Celestino, Ranran Wu, Eunice Murage, Rachelle Spencer, Jennifer B. Dennison, Jody Vykoukal, James P. Long, Kim Anh Do, Charles Drescher, Karen Lu, Zhen Lu, Robert C. Bast, Sam Hanash, Johannes F. Fahrmann
Journal: Clinical Cancer Research (2022)

To assess the contributions of circulating metabolites for improving upon the performance of the risk of ovarian malignancy algorithm (ROMA) for risk prediction of ovarian cancer among women with ovarian cysts.
A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer
Authors: Kathy Han, Anthony Fyles, Tina Shek, Jennifer Croke, Neesha Dhani, David D'Souza, Ting-Yim Lee, Naz Chaudary, Jeffrey Bruce, Melania Pintilie, Rob Cairns, Douglass Vines, Sara Pakbaz, David Jaffray, Ur Metser, Marjan Rouzbahman, Michael Milosevic, Marianne Koritzinsky
Journal: Clinical Cancer Research (2022)

Tumor hypoxia is associated with poor response to radiation (RT). We previously discovered a novel mechanism of metformin: enhancing tumor RT response by decreasing tumor hypoxia. We hypothesized that metformin would decrease tumor hypoxia and improve cervical cancer response to RT.A window-of-opportunity, phase II randomized trial was performed in stage IB-IVA cervical cancer. Patients underwent screening positron emission tomography (PET) imaging with hypoxia tracer fluoroazomycin arabinoside (FAZA). Only patients with FAZA uptake (hypoxic tumor) were included and randomized 2:1 to receive metformin in combination with chemoRT or chemoRT alone. A second FAZA-PET/CT scan was performed after 1 week of metformin or no intervention (control). The primary endpoint was a change in fractional hypoxic volume (FHV) between FAZA-PET scans, compared using the Wilcoxon signed-rank test. The study was closed early due to FAZA availability and the COVID-19 pandemic.Of the 20 consented patients, 6 were excluded due to no FAZA uptake and 1 withdrew. FHV of 10 patients in the metformin arm decreased by an average of 10.2% (44.4%-34.2%) ± SD 16.9% after 1 week of metformin, compared with an average increase of 4.7% (29.1%-33.8%) ± 11.5% for the 3 controls (P = 0.027). Those with FHV reduction after metformin had significantly lower MATE2 expression. With a median follow-up of 2.8 years, the 2-year disease-free survival was 67% for the metformin arm versus 33% for controls (P = 0.09).Metformin decreased cervical tumor hypoxia in this trial that selected for patients with hypoxic tumor. See related commentary by Lyng et al., p. 5233.
Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma
Authors: Hanna Meister, Thomas Look, Patrick Roth, Steve Pascolo, Ugur Sahin, Sohyon Lee, Benjamin D. Hale, Berend Snijder, Luca Regli, Vidhya M. Ravi, Dieter Henrik Heiland, Charles L. Sentman, Michael Weller, Tobias Weiss
Journal: Clinical Cancer Research (2022)

Abstract Purpose: Most chimeric antigen receptor (CAR) T-cell strategies against glioblastoma have demonstrated only modest therapeutic activity and are based on persistent gene modification strategies that have limited transgene capacity, long manufacturing processes, and the risk for uncontrollable off-tumor toxicities. mRNA-based T-cell modifications are an emerging safe, rapid, and cost-effective alternative to overcome these challenges, but are underexplored against glioblastoma. Experimental Design: We generated mouse and human mRNA-based multifunctional T cells coexpressing a multitargeting CAR based on the natural killer group 2D (NKG2D) receptor and the proinflammatory cytokines IL12 and IFNα2 and assessed their antiglioma activity in vitro and in vivo. Results: Compared with T cells that either expressed the CAR or cytokines alone, multifunctional CAR T cells demonstrated increased antiglioma activity in vitro and in vivo in three orthotopic immunocompetent mouse glioma models without signs of toxicity. Mechanistically, the coexpression of IL12 and IFNα2 in addition to the CAR promoted a proinflammatory tumor microenvironment and reduced T-cell exhaustion as demonstrated by ex vivo immune phenotyping, cytokine profiling, and RNA sequencing. The translational potential was demonstrated by image-based single-cell analyses of mRNA-modified T cells in patient glioblastoma samples with a complex cellular microenvironment. This revealed strong antiglioma activity of human mRNA-based multifunctional NKG2D CAR T cells coexpressing IL12 and IFNα2 whereas T cells that expressed either the CAR or cytokines alone did not demonstrate comparable antiglioma activity. Conclusions: These data provide a robust rationale for future clinical studies with mRNA-based multifunctional CAR T cells to treat malignant brain tumors.
Rapid in vivo multiplexed editing (RIME) of the adult mouse liver
Authors: Takeshi Katsuda, Hector Cure, Jonathan Sussman, Kamen P. Simeonov, Christopher Krapp, Zoltan Arany, Markus Grompe, Ben Z. Stanger
Journal: Hepatology (2022)

Assessing mammalian gene function in vivo has traditionally relied on manipulation of the mouse genome in embryonic stem cells or perizygotic embryos. These approaches are time-consuming and require extensive breeding when simultaneous mutations in multiple genes is desired. The aim of this study is to introduce a rapid in vivo multiplexed editing (RIME) method and provide proof of concept of this system.
Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH
Authors: Darren Jun Hao Tan, Veronica Wendy Setiawan, Cheng Han Ng, Wen Hui Lim, Mark D. Muthiah, Eunice X. Tan, Yock Young Dan, Lewis R. Roberts, Rohit Loomba, Daniel Q. Huang
Journal: Hepatology (2022)

Background and Aim: The etiology of liver diseases has changed in recent years, but its impact on the comparative burden of liver cancer between males and females is unclear. We estimated sex differences in the burden of liver cancer across 204 countries and territories from 2010 to 2019. Approach and Result: We analyzed temporal trends in the burden of liver cancer using the methodology framework of the 2019 Global Burden of Disease study. We estimated annual frequencies and age‐standardized rates (ASRs) of liver cancer incidence, death, and disability‐adjusted life‐years (DALYs) by sex, country, region, and etiology of liver disease. Globally in 2019, the frequency of incident cases, deaths, and DALYs due to liver cancer were 376,483, 333,672, and 9,048,723 in males, versus 157,881, 150,904, and 3,479,699 in females. From 2010 to 2019, the incidence ASRs in males increased while death and DALY ASRs remained stable; incidence, death, and DALY ASRs in females decreased. Death ASRs for both sexes increased only in the Americas and remained stable or declined in remaining regions. In 2019, hepatitis B was the leading cause of liver cancer death in males, and hepatitis C in females. From 2010 to 2019, NASH had the fastest growing death ASRs in males and females. The ratio of female‐to‐male death ASRs in 2019 was lowest in hepatitis B (0.2) and highest in NASH (0.9). Conclusions: The overall burden of liver cancer is higher in males, although incidence and death ASRs from NASH‐associated liver cancer in females approach that of males.
Analysis of Select Dietary Supplement Products Marketed to Support or Boost the Immune System
Authors: Cindy Crawford, Bharathi Avula, Andrea T. Lindsey, Abraham Walter, Kumar Katragunta, Ikhlas A. Khan, Patricia A. Deuster
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Cold, flu, and immunity dietary supplement product sales have skyrocketed since the start of the COVID-19 pandemic. Supporting or boosting the immune system has become an important reason for using dietary supplements, and many consumers are purchasing products through online platforms. <h3>Objectives</h3> To examine whether select dietary supplement products advertised as supporting or boosting the immune system are accurately labeled according to the Supplement Facts label of listed ingredients and to qualitatively describe the product labels' characteristics in terms of claims made. <h3>Design, Setting, and Participants</h3> In this case series, 30 featured immune health dietary supplements were selected and purchased from Amazon.com in May 2021. Product analysis was performed using liquid chromatography–mass spectrometry. The list of ingredients detected through analysis for each product was compared with the ingredients on the product's Supplement Facts label to determine whether the product's label was accurate. Claims made on product labels were also evaluated by using the Operation Supplement Safety Scorecard's set of questions to describe the labels' characteristics. <h3>Results</h3> A total of 30 select dietary supplement products were evaluated. Thirteen of the 30 products had accurate labels based on the product analysis. Of the 17 products with inaccurate labels, 13 had ingredients listed on the labels that were not detected through analysis, such that their labels were misbranded. Nine products had substances detected that were not claimed on the product labels, some of which may be considered adulterated. Five were misbranded and contained additional components not claimed on the label. No product had third-party certification seals present on the packaging. Ten of the 13 products with accurate labels received a score of 4 or more when applying the Operation Supplement Safety Scorecard, meaning the product was "likely okay/less risky." <h3>Conclusions and Relevance</h3> In this case series study, most of the products tested had inaccurate labels and claims that were inconsistent with requirements the US Food and Drug Administration has put forward for dietary supplements. Quality control measures seem to be insufficient for most of these select products, and claims made on labels may be misleading consumers who purchase products.
From Individualized Interactions to Standardized Schedules: A History of Time Organization in U.S. Outpatient Medicine
Authors: Michelle-Linh T. Nguyen, Samuel V. Schotland, Joel D. Howell
Journal: Annals of Internal Medicine (2022)

Many outpatient physicians and patients feel that current scheduling systems do not afford enough time for direct patient-physician interaction, leaving patients feeling unheard and physicians feeling demoralized. This dissatisfaction degrades patients' trust in the health care system and contributes to workforce moral injury and burnout. In the hopes of understanding the roots of this time stress and helping to guide future decisions about how to organize physicians' time, this article describes changes in the organization of U.S. outpatient physicians' time, starting from care at home in the late 19th century. It discusses the origins of the appointment system, which was invented to be highly personalized, with assistants adjusting appointment durations to accommodate clinical activities, specific patient needs, and individual physician proclivities. The article then describes how centralization of appointment scheduling became more common as U.S. medicine became increasingly consolidated into larger and larger groups and health systems. This distanced schedulers from the people and care they were organizing and necessitated standardized appointment durations, which did not accommodate individual patient and physician needs. With the rise of managerialism, schedulers became increasingly accountable to administrators rather than patients and physicians. Whereas early appointment systems depended on personal connection between schedulers and the physicians and patients they supported, today's schedulers have few such interactions. The widespread shift to centralized scheduling and standardized time slots has contributed to misalignment among time allocation, patient care, and health care workforce well-being and is likely exacerbating ongoing tensions among patients, physicians, and administrators.
Chronic conditions, late mortality, and health status after childhood AML: a Childhood Cancer Survivor Study report
Authors: Lucie M. Turcotte, Jillian A. Whitton, Wendy M. Leisenring, Rebecca M. Howell, Joseph P. Neglia, Rachel Phelan, Kevin C. Oeffinger, Kirsten K. Ness, William G. Woods, E. Anders Kolb, Leslie L. Robison, Gregory T. Armstrong, Eric J. Chow
Journal: Blood (2022)
Visualizing patterns and gaps in transgender sexual and reproductive health: A bibliometric and content analysis of literature (1990–2020)
Authors: Liam Gary Arnull, Anuj Kapilashrami, Margaret Sampson
Journal: International Journal of Transgender Health (2021)

Transgender people face numerous obstacles to accessing adequate, affordable, and appropriate sexual and reproductive health (SRH) services as outlined by the UN's Sustainable Development Goal 3.7 target of achieving universal access to SRH services by 2030. However, transgender SRH sits as a poorly researched area within public health that makes it difficult to understand the current dilemmas facing transgender SRH. This article reports the findings of a study aimed at taking stock of global research in transgender SRH.A bibliometric analysis, used to gain insights from the retrieved literature's metadata, alongside a content analysis were utilized to examine the growth, impact, and content of retrieved articles.Nine hundred fourteen journal articles were retrieved, predominately in English (884; 96.7%). These involved 3653 authors from 46 affiliated countries. Most frequent keywords included HIV, PrEP, and gender identity; corresponding to the SRH issues studied, namely HIV/AIDs and gender reassignment. Top cited and overall articles originated heavily from US affiliated authors. Content analysis outlined the articles' inclusion of the transgender community to largely have a mixed focus with cisgender people in research, these articles largely disease-focused and conducted within cities in the United States.Growth in transgender SRH research was minimal until the early-2010s, after which a steep rise can be observed. Research retrieved has a disproportionate clinical and biomedical focus around HIV and related STI issues suggesting a failure to engage with reproductive justice and more comprehensive rights-based understanding of SRH. The sustained use of derogative language suggests a need for greater inclusion and awareness of trans identities within research and publishing. The dominance of the United States in authorship and as a site of research establishes the need for more geographically diverse research, trans, and LMIC-led research enquiry and creating greater opportunities for cross-cultural, comparative, and collaborative scholarly work.
“It felt like they were trying to destabilise us”: Parent assessment in UK children’s gender services
Authors: Cal Horton
Journal: International Journal of Transgender Health (2021)

Background: Pediatric gender clinics have a long history of analyzing and scrutinizing parents of trans children. At present, gender services in countries like the UK continue to hold clinical sessions with parents of pre-adolescent transgender children, sometimes extending over many years. Clinician viewpoints dominate the limited existing literature, with little analysis of the perspectives of parents of trans children.Aims: The study aimed to understand the experiences that parents of socially transitioned pre-adolescent trans children have had in UK gender clinics.Methods: Data were drawn from semi-structured qualitative interviews with 30 UK-based parents of socially transitioned trans children – children who socially transitioned, for example, changed pronoun, under the age of eleven. This article analyzed a subset of a wider dataset, focusing on data from 23 parents relating to parental engagement with UK NHS gender clinics before their child reached adolescence.Results: Themes emerging from the dataset included parents feeling under a microscope, and parents finding gender clinic sessions judgemental, intrusive and inappropriate. Interviewees reported clinician discouragement of listening to and validating their children, as well as a lack of emotional support.Discussion: The article presents evidence of continued pathologisation and problematisation of childhood gender diversity in parental engagements with UK children's gender clinics. It concludes by contrasting current UK practice as described in parental accounts with gender affirmative approaches to supporting parents of trans children.